| 1356 |
National Cancer Institute |
Html |
en |
Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of metastatic cancer that has spread from an unidentified primary tumor. |
| general cancer information | 0.411851 |
| treatment | 0.656267 |
| cancer treatment | 0.493001 |
| breast cancer cells | 0.486603 |
| primary cancer | 0.600191 |
| new cancer treatments | 0.408458 |
| Peritoneal Cancer Treatment | 0.426103 |
| cancer cells | 0.712358 |
| tissue | 0.443805 |
| malignant tumor cells | 0.423112 |
| body | 0.560831 |
| type | 0.447878 |
| Cancer Information Service | 0.414189 |
| Squamous Neck Cancer | 0.400297 |
| PDQ cancer information | 0.512966 |
| clinical trial search | 0.39505 |
| treatment clinical trials | 0.437756 |
| certain changes | 0.407705 |
| National Cancer Institute | 0.54586 |
| clinical trials | 0.823063 |
| normal cells | 0.410928 |
| cancer information summary | 0.471688 |
| clinical trial | 0.588388 |
| new treatment | 0.44726 |
|
| breast cancer prevention | 0.400005 |
| primary cancer site | 0.517081 |
| cancer tissue | 0.403216 |
| patients | 0.429603 |
| Cancer Care page | 0.397493 |
| PDQ summary | 0.435669 |
| treatment clinical trial | 0.401935 |
| PDQ Adult Treatment | 0.398071 |
| NCI PDQ cancer | 0.432436 |
| cancer research process | 0.400715 |
| cancer clinical trials | 0.44656 |
| tests | 0.388491 |
| lymph nodes | 0.409196 |
| Unknown Primary Treatment | 0.395812 |
| carcinoma | 0.39749 |
| primary cancer depend | 0.439856 |
| lymph node | 0.431668 |
| radiation therapy | 0.485838 |
| Treatment Editorial Board | 0.413559 |
| cancer information summaries | 0.411898 |
| comprehensive cancer information | 0.411754 |
| cancer | 0.945761 |
| standard treatment | 0.426236 |
|
CLICK HERE |
| 1363 |
National Cancer Institute |
Html |
en |
Male Breast Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of male breast cancer. |
| AI vs | 0.370903 |
| mismatch repair mutations | 0.369221 |
| Eggemann et al. | 0.365773 |
| female breast cancer | 0.551031 |
| breast cancer patients. | 0.466631 |
| GnRH analogue | 0.380989 |
| PDQ cancer information | 0.414389 |
| Information About Breast | 0.42794 |
| Preoperative Systemic Therapy | 0.38272 |
| randomized phase | 0.368125 |
| tamoxifen | 0.45543 |
| clinical trial | 0.36672 |
| Intraductal cancer | 0.367134 |
| hormone-releasing hormone | 0.373589 |
| Breast Cancer section | 0.560693 |
| systemic therapy | 0.39727 |
| Postoperative Systemic Therapy | 0.381557 |
| AI therapy | 0.401771 |
| PDQ Adult Treatment | 0.387754 |
| hormonal therapy | 0.380314 |
| retrospective analysis | 0.368006 |
| gonadotropin-releasing hormone | 0.373142 |
| hormone receptor-positive breast | 0.492818 |
| breast cancer. | 0.41194 |
| German Breast Group | 0.488303 |
|
| et al. | 0.433842 |
| Comprehensive Cancer Database | 0.381494 |
| nonpolyposis colorectal cancer | 0.384245 |
| stage breast cancer | 0.454368 |
| Ding et al. | 0.368736 |
| male breast cancer | 0.671805 |
| Lymph node involvement | 0.37157 |
| Early/Localized/Operable Breast Cancer | 0.46567 |
| median follow-up | 0.370308 |
| ductal cancer | 0.367207 |
| Breast Cancer Treatment | 0.527076 |
| PDQ Editorial Boards | 0.382108 |
| pdq summary | 0.467559 |
| adjuvant endocrine therapy | 0.440604 |
| early-stage hormone | 0.372333 |
| breast cancer | 0.962266 |
| adjuvant treatment options | 0.385121 |
| AJCC Stage Groupings | 0.374688 |
| Zagouri et al. | 0.367325 |
| male breast cancers | 0.446407 |
| common tumor type. | 0.372879 |
| specific treatment modalities | 0.365164 |
| analogue versus AI | 0.45406 |
| receptor-positive breast cancer | 0.49928 |
|
CLICK HERE |
| 1428 |
National Cancer Institute |
Html |
null |
Retinoblastoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of retinoblastoma in children. |
|
|
CLICK HERE |
| 1828 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia linfoblástica aguda en adultos (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda en adultos. |
| Italy Leukemia Group | 0.510748 |
| prognostic factors | 0.523487 |
| in adults | 0.649162 |
| tirosina cinasa bcr-abl | 0.513926 |
| largo plazo | 0.507147 |
| leukemia group | 0.574628 |
| or fab l3 | 0.5087 |
| LLA Ph1 | 0.523666 |
| chronic myeloid leukemia | 0.519002 |
| Thiel E | 0.520173 |
| TMO autógeno | 0.523146 |
| adults with | 0.569541 |
| leucemia mielógena | 0.512104 |
| donante fraterno | 0.513552 |
| lymphocytic leukemia | 0.529118 |
| Löffler H | 0.510187 |
| LLA recién | 0.516678 |
| induction regimen with | 0.509327 |
| in adults with | 0.545834 |
| patients with | 0.533511 |
| complete remission | 0.509903 |
| leucemia mielocÃtica aguda | 0.512148 |
| multicenter study | 0.514475 |
| adults with standard-risk | 0.510496 |
| myeloid leukemia | 0.519806 |
|
| marrow transplantation | 0.523773 |
| leucemia aguda | 0.509415 |
| leucemia linfoblástica aguda | 0.65786 |
| TMO alogénico | 0.56508 |
| bone marrow transplantation | 0.52273 |
| morfologÃa l3 | 0.522238 |
| Hoelzer D | 0.525554 |
| leukemia with | 0.523655 |
| Adult Leukemia Study | 0.507091 |
| Northern Italy Leukemia | 0.510296 |
| Horowitz MM | 0.508541 |
| LLA L3 | 0.549875 |
| International ALL Trial | 0.508909 |
| PDQ Tratamiento | 0.509128 |
| Dodge RK | 0.508725 |
| Brief-duration high-intensity chemotherapy | 0.50796 |
| bone marrow transplant | 0.513671 |
| Clin Oncol | 0.534506 |
| sistema nervioso central | 0.584696 |
| bone marrow | 0.527725 |
| with small noncleaved-cell | 0.509543 |
| acute lymphoblastic leukemia | 0.981898 |
| leukemia with hyper-CVAD | 0.507761 |
| lla recidivante quimioterapia | 0.519565 |
|
CLICK HERE |
| 1869 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma de tejido blando infantil (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del sarcoma de tejido blando infantil. |
| Pediatric Oncology | 0.427738 |
| Childhood soft tissue | 0.412657 |
| Sarcoma Group | 0.408529 |
| soft part sarcoma | 0.421702 |
| Pediatr Surg Int | 0.410488 |
| tumor >5 cm | 0.40873 |
| Neonatal soft tissue | 0.41137 |
| pediatric nonrhabdomyosarcoma soft | 0.423413 |
| soft-tissue sarcoma | 0.42357 |
| oncology group study | 0.42018 |
| sarcoma necessary after | 0.409292 |
| Children's Oncology Group | 0.423153 |
| sarcoma results | 0.408962 |
| undifferentiated sarcoma | 0.409416 |
| 5th ed | 0.408863 |
| pediatric soft tissue | 0.468096 |
| Weiss's Soft Tissue | 0.465072 |
| soft tissue sarcoma | 0.984779 |
| low-grade fibromyxoid sarcoma | 0.417727 |
| Jude Children Research | 0.411214 |
| lower extremity sarcomas | 0.408827 |
| nonrhabdomyosarcoma soft | 0.450499 |
| sarcoma patients | 0.409132 |
| End Results | 0.409463 |
| Surg Pathol | 0.410619 |
|
| cuello sarcoma | 0.408715 |
| Ferrari A | 0.410275 |
| Pediatr Blood Cancer | 0.449691 |
| Cancer Staging Manual | 0.440273 |
| Weiss SW | 0.438749 |
| Genes Chromosomes Cancer | 0.409368 |
| Translocation-related sarcomas | 0.408627 |
| Surg Oncol | 0.422483 |
| Adult-type soft tissue | 0.411539 |
| Sarcomas embrionarios | 0.408595 |
| Pediatr Surg | 0.44479 |
| part sarcoma fuses | 0.409332 |
| Clin Oncol | 0.434253 |
| Children's Research Hospital | 0.410798 |
| Goldblum JR | 0.438633 |
| sarcomas with surgery | 0.409572 |
| soft tissue tumors | 0.508399 |
| Pediatric Oncology Group | 0.420884 |
| >5 cm | 0.415115 |
| retroperitoneo sarcoma | 0.408795 |
| round cell tumor | 0.41657 |
| Oncology Group | 0.440064 |
| localized soft-tissue sarcomas | 0.40921 |
| AJCC Cancer Staging | 0.461396 |
|
CLICK HERE |
| 2066 |
National Cancer Institute |
Html |
es |
Los cuidados al final de la vida de personas con cáncer |
Hoja informativa que responde algunas de las preguntas que tienen muchos pacientes, sus familiares y quienes cuidan de ellos acerca del final de la vida. |
| desechos quizás | 0.586339 |
| pequeñas porciones | 0.540804 |
| alcance objetos | 0.559532 |
| suficientes glóbulos | 0.562578 |
| causa hinchazón | 0.558057 |
| dosis correctos | 0.546349 |
| médicos cuánto tiempo | 0.63336 |
| suficiente oxÃgeno | 0.652738 |
| cuánto tiempo | 0.903324 |
| suficiente tejido | 0.550065 |
| paciente experimenta sÃntomas | 0.986626 |
| paciente quizás | 0.789052 |
| considerable agitación | 0.540843 |
| quizás querrán | 0.579319 |
|
| menor flujo | 0.542617 |
| presente somnolencia | 0.544492 |
| reducida capacidad | 0.540414 |
| persona enferma causa | 0.731054 |
| malos dÃas | 0.539357 |
| mejores cuidadores | 0.583437 |
| Mayor debilidad | 0.544974 |
| falsas esperanzas | 0.572246 |
| siguientes situaciones | 0.566454 |
| cuerpo boca | 0.542456 |
| familia esté lista | 0.658292 |
| paciente presente incontinencia | 0.756496 |
| persona quizás | 0.668635 |
|
CLICK HERE |
| 2068 |
National Cancer Institute |
Html |
es |
Marcadores de tumores |
Hoja informativa que explica lo que son los marcadores de tumores y responde preguntas sobre su uso para el diagnóstico y tratamiento del cáncer. |
| Bast RC Jr | 0.727949 |
| cancer screening | 0.603977 |
| Gray RJ | 0.462067 |
| randomized european study | 0.51305 |
| Asociación Estadounidense | 0.468124 |
| estudio plco | 0.461327 |
| Bigbee W | 0.467579 |
| amplia gama | 0.464843 |
| afecciones benignas | 0.671952 |
| Herberman RB | 0.469893 |
| Prevention Research | 0.463207 |
| BC Decker Inc | 0.509079 |
| Clinical Laboratory Improvement | 0.519898 |
| Cancer Screening Randomized | 0.544857 |
| Controlled Trial | 0.467216 |
| riesgo intermedio | 0.462476 |
| Clinical Practice | 0.47196 |
| ecografÃa transvaginal | 0.471751 |
| Makower DF | 0.466396 |
| estudio tailorx | 0.460805 |
| ¿Cuáles marcadores | 0.637902 |
| 21-gene expression assay | 0.514014 |
|
| Hugosson J | 0.463892 |
| Instituto Nacional | 0.461324 |
| screening trial specimens | 0.541412 |
| OncologÃa ClÃnica | 0.463202 |
| tumor markers | 0.619108 |
| Andriole G | 0.463781 |
| Mortality results from | 0.526447 |
| Quality Requirements | 0.470424 |
| Kufe DW | 0.468535 |
| Black A | 0.461077 |
| 6th ed | 0.467056 |
| Oncotype DX® | 0.469566 |
| situaciones benignas | 0.492829 |
| PubMed Abstract | 0.928354 |
| tratamientos resultantes | 0.466203 |
| Buys SS | 0.460749 |
| BioquÃmica ClÃnica | 0.461341 |
| Pollock RE | 0.46616 |
| New England Journal | 0.930005 |
| Roobol MJ | 0.466517 |
| Sparano JA | 0.466154 |
| hoja informativa estadificación | 0.539118 |
|
CLICK HERE |
| 3429 |
National Cancer Institute |
Html |
es |
Agua fluorada |
Hoja informativa que examina los estudios realizados sobre la posible conexión entre el agua fluorada y el cáncer. |
| Villanacci JF | 0.447057 |
| Feltbower RG | 0.446597 |
| fluoruro ingerido | 0.954566 |
| Mortality Weekly Report | 0.483586 |
| vasta cantidad | 0.449716 |
| carcinogenicity studies with | 0.478781 |
| bajas. Muchos estudios | 0.468962 |
| Water Fluoridation Statistics | 0.487645 |
| Toxicology Program rodent | 0.480514 |
| Napier TS | 0.445775 |
| Ewing sarcoma diagnosed | 0.483942 |
| Great Britain | 0.443018 |
| Disease Control | 0.536557 |
| public drinking water | 0.505168 |
| National Academy | 0.558901 |
| Instituto Nacional | 0.520062 |
| agua ayuda | 0.629089 |
| Environmental Health | 0.58081 |
| Related Programs | 0.449277 |
| Estados Unidos | 0.666074 |
| Kim FM | 0.441491 |
| resultados contradictorios | 0.444365 |
| Ingested Fluoride | 0.54922 |
| PubMed Abstract | 0.93552 |
|
| among 0-49-year-olds | 0.445423 |
| Williams PL | 0.44275 |
| salud pública | 0.65032 |
| Ad Hoc Subcommittee | 0.477798 |
| International Journal | 0.533052 |
| Blakey K | 0.445319 |
| Dental Research | 0.46834 |
| Parslow RC | 0.444263 |
| Health Effects | 0.572713 |
| Grand Rapids | 0.447598 |
| Hejtmancik MR | 0.446466 |
| Environmental Health Sciences | 0.528481 |
| Hayes C | 0.441487 |
| Toft JD | 0.447997 |
| drinking water | 0.564502 |
| public health | 0.755217 |
| National Institute | 0.45889 |
| Coordinate Environmental Health | 0.506784 |
| prevent dental caries | 0.542747 |
| Retrieved August | 0.565765 |
| Salud Ambiental | 0.441563 |
| National Research Council | 0.675505 |
| siglo xx | 0.446805 |
| Public Health Service | 0.715782 |
|
CLICK HERE |
| 3582 |
National Cancer Institute |
Html |
en |
Frederick National Laboratory for Cancer Research |
The FNLCR combines private sector business practices with government infrastructure to conduct research and development in cancer and AIDS. |
| Frederick National Lab | 0.679634 |
| Development Center—one | 0.586036 |
| Federally Funded Research | 0.723777 |
| FNLCR | 0.617129 |
| biomarker identification | 0.53533 |
| animal sciences | 0.53568 |
| national resource | 0.541398 |
| government agencies | 0.530109 |
| human clinical trials | 0.61809 |
| preclinical assay development | 0.712354 |
| oncology-focused computational science | 0.628628 |
| cancer research laboratories | 0.757218 |
| early development | 0.553877 |
| research reagents | 0.571396 |
| NCI | 0.666268 |
| genetically engineered mouse | 0.603734 |
| preclinical research | 0.638044 |
| nonprofit research organizations | 0.690454 |
| broad charter | 0.538883 |
| Leidos Biomedical Research | 0.735212 |
| United States | 0.647036 |
| Nanotechnology Characterization Laboratory | 0.625355 |
| RAS family | 0.527528 |
| clinical practice | 0.533965 |
|
| NCI investigators | 0.632716 |
| significant cancer research | 0.722685 |
| translational genomics | 0.544933 |
| cancer research | 0.952491 |
| private sector business | 0.653242 |
| new drug development | 0.647375 |
| government sponsors | 0.545164 |
| biomedical research community | 0.670235 |
| development needs | 0.584975 |
| cancer researchers | 0.562687 |
| clinical operations | 0.542191 |
| Frederick National Laboratory | 0.684108 |
| government infrastructure | 0.535486 |
| technical staff | 0.530406 |
| preclinical model development | 0.704349 |
| private sector resources | 0.635668 |
| FNLCR programs | 0.564698 |
| National lab staff | 0.628876 |
| biomedical computing | 0.548325 |
| new cancer therapies | 0.637914 |
| frozen tumor samples | 0.605424 |
| nanotechnology applications | 0.53469 |
| cancer research enterprise | 0.705608 |
| basic research | 0.59861 |
|
CLICK HERE |
| 3604 |
National Cancer Institute |
Html |
null |
Advancing Precision Medicine in Oncology |
Multiyear funding for the Precision Medicine Initiative® (PMI) will help accelerate progress toward the promising new era of precision medicine in oncology. |
|
|
CLICK HERE |